Multiple SclerosisAn extension <strong>of</strong> the double‐blind, r<strong>and</strong>omized, placebo‐controlled, parrallel‐group, multicenter study evaluatingsafety, tolerability <strong>and</strong> effect on MRI lesion parameters <strong>of</strong> FTY720 vs placebo in patients with relapsing multiplesclerosisA 12‐month double‐blind, r<strong>and</strong>omized, multicenter, active‐controlled, parallel‐group study comparing theefficacy <strong>and</strong> safety <strong>of</strong> 0.5mg <strong>and</strong> 1.25mg fingolimod (FTY720) administered orally once daily versus interferon β‐1a (Avonex®) administered i.m. once weekly in patients with relapsing‐remitting multiple sclerosisRetinal ToxicityLong term (3 years) ophthalmic safety <strong>and</strong> cardiac efficacy <strong>and</strong> safety <strong>of</strong> ivabradine administered at thetherapeutic recommended doses (2.5/5/7.5 mg b.i.d.) on top <strong>of</strong> anti anginal background therapy, to patients withchronic stable angina pectoris. An international, double‐blind placebo controlled studyRetinitis PigmentosaAn Exploratory, Multicenter, Patient‐masked, Dose‐escalation, Paired‐eye Comparison, Sham‐controlled, 6‐Month (Plus 6‐Month Extension) Study to Evaluate the Safety <strong>and</strong> Effects on Visual Function <strong>of</strong> 100ug, 200 ug,<strong>and</strong> 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS)Applicator System in Patients with Retinitis PigmentosaUveitis136An 8‐week, multicenter, masked, r<strong>and</strong>omized trial (with an 18‐week masked extension) to assess the safety <strong>and</strong>efficacy <strong>of</strong> 700 μg <strong>and</strong> 350 μg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicatorsystem compared with sham DEX PS DDS applicator system in the treatment <strong>of</strong> non‐infectious ocularinflammation <strong>of</strong> the posterior segment in patients with intermediate uveitisObservational StudiesFunctional Genomics <strong>of</strong> the Retina in Health <strong>and</strong> Disease (EVI‐GENORET)The phenotyping component <strong>of</strong> EVI‐GENORET Project is collecting data on well‐defined phenotypes <strong>of</strong> patientswith Age‐Related Macular Degeneration <strong>and</strong> Monogenic Retinal Dystrophies. A case report <strong>for</strong>m (e‐CRF) hasbeen developed <strong>and</strong> is fully implemented as an internet based Database.Medical doctors from AIBILI are also including data according to this specific protocol to the consortiumdatabase
StaffDirectorMaria Luísa Ribeiro, MD, MScPrincipal InvestigatorsMaria Luísa Ribeiro, MD, MScLilianne Duarte, MDConceição Lobo, MD PhDEduardo Silva, MD PhDJoão Figueira, MD MScJoaquim Murta, MD PhDJosé Cunha‐Vaz, MD PhDRufino Silva, MD PhDRui Daniel Proença, MD PhDInvestigatorsAna Esmeralda Costa, MDAndreia Rosa, MDHelena Azevedo, MD MScIsabel Pires, MDJoaquim Mira, MDJorge Henriques, MDJosé Moura Pereira, MDLuís Cristóvão, MDM.ª João Quadrado, MD MScM.ª Júlia Veríssimo, MDM.ª Luz Cachulo, MDMarília Rocha, PharmDMário Alfaiate, MD MScMário Cruz, MDPatrícia Leitão Carvalho, MDPaula Magro, MDPedro Faria, MDPedro Fonseca, MDStudy CoordinatorsAdozinda SimãoCarla DuarteCatarina NevesLiliana CarvalhoRenata CastanheiraAdministrativeIsabel SimõesS<strong>and</strong>ra Cristina PardalTechnicians <strong>for</strong> Diagnostic ProceduresAldina Reis, MScAna Rita SantosAntónio Pedro MeloGraciete AbreuMário SoaresMaria Pedro SilvaNursesAlex<strong>and</strong>ra TavaresCarla S<strong>of</strong>ia Duarte, BScEugénia CardosoMaria do Céu Simões137ContactsMaria Luísa RibeiroPhone: +351 239 480 128Fax: +351 239 483 593E‐mail: lr@aibili.pt
- Page 7 and 8:
General ObjectivesThe CNC major mis
- Page 11 and 12:
OrganizationThe Center for Neurosci
- Page 13:
Microbiology | Milton CostaMicrobio
- Page 16 and 17:
per year) will be proposed by the g
- Page 18 and 19:
Neuroprotection and Neurogenesis in
- Page 20 and 21:
Retinal Dysfunction and Neurogenesi
- Page 22 and 23:
Glutamatergic synapses | Head: Ana
- Page 24 and 25:
Neuronal Cell Death and Neuroprotec
- Page 26 and 27:
Molecular Mechanisms of Disease | H
- Page 28 and 29:
PublicationsAgasse F, Bernardino L,
- Page 30 and 31:
Santiago AR, Carvalho, CM, Carvalho
- Page 32 and 33:
“Nano‐transportadores de base l
- Page 34 and 35:
Vectors and Gene Therapy GroupM. Co
- Page 36 and 37:
Molecular Systems Biology | Head: A
- Page 38 and 39:
Vectors and Gene Therapy | Head: Ma
- Page 40 and 41:
PublicationsAlves S, Nascimento‐F
- Page 43 and 44:
Area C | Cell and Molecular Toxicol
- Page 45 and 46:
Mitochondrial Toxicology and Pharma
- Page 47:
Pharmacometrics GroupAmílcar Falc
- Page 50 and 51:
Free Radicals and Antioxidants in B
- Page 52 and 53:
Pharmacometrics | Head: Amílcar Fa
- Page 54 and 55:
Correia S, Carvalho C, Santos MS, P
- Page 57 and 58:
Area D | MicrobiologyCoordinator |
- Page 59:
Microbiology of Extreme Environment
- Page 62 and 63:
Medical Mycology - Yeast Research |
- Page 65 and 66:
Area E | Biophysics and Biomedical
- Page 67 and 68:
Inorganic Biochemistry and Molecula
- Page 69 and 70:
Inorganic Biochemistry and Molecula
- Page 71 and 72:
Cell Biophysics |Head: Luís Martin
- Page 73:
Sobral AJFN, Justino LLG, Santos AC
- Page 76 and 77:
Future PlansThere is an enormous we
- Page 78 and 79:
Paula MotaSara M. Diniz Martins Lop
- Page 80 and 81:
Biology of Reproduction and Human F
- Page 82 and 83:
Insulin Resistance and Adipocyte |
- Page 85 and 86: Biomedical Inter‐Institutional Re
- Page 87 and 88: 3. Pediatric Research: metabolic di
- Page 89 and 90: PublicationsSantos MJ, Cleto S, Men
- Page 91: 7. Research in brain cancer: geneti
- Page 94 and 95: Grafting SVZ neural stem cell cultu
- Page 96 and 97: Structure‐function analysis of th
- Page 98 and 99: Anticancer Effects of of Phytochemi
- Page 100 and 101: Investigaciones Biomédicas “Albe
- Page 102 and 103: Participation in the organization o
- Page 104 and 105: May 2008Member of the organizing co
- Page 106 and 107: 106
- Page 108 and 109: Genome BiologyFebruary 25 ‐ 27Isa
- Page 110 and 111: Seminars2008 Series | CNC Audithori
- Page 112 and 113: 13.6.2008Cells caught in the act: M
- Page 114 and 115: 5.12.2008Unexpected fate and functi
- Page 116 and 117: Elisabete Ferreiro“Cross‐talk b
- Page 118 and 119: Ana Isabel Vicente Rafael“Estudos
- Page 120 and 121: Rosete Pais“Papilomavirus humano
- Page 122 and 123: 122
- Page 124 and 125: 124
- Page 126 and 127: FLOW CYTOMETRY UNITHead of Unit: Is
- Page 128 and 129: MASS SPECTROMETRY UNITHead of Unit:
- Page 130 and 131: 130
- Page 132 and 133: Amino Acid AnalysisOur laboratory r
- Page 134 and 135: 2. Areas of Expertise / Research /
- Page 138 and 139: 2.2. Centre for Bioavailability Stu
- Page 140 and 141: StaffCoordinatorTice Macedo, MD, Ph
- Page 142 and 143: 142
- Page 144 and 145: Compatible solutes from extremophil
- Page 146 and 147: Proteases aspárticas secretadas em
- Page 148 and 149: Mecanismos de plasticidade sinápti
- Page 150 and 151: Clivagem dos transportadores vesicu
- Page 152 and 153: ʺBIOINK ‐ Aprendizagem increment
- Page 154 and 155: 154
- Page 156 and 157: Henrique Faneca (Auxiliar Inv., CNC
- Page 158 and 159: Liliana Bernardino 100Luis Miguel E
- Page 160 and 161: João Teixeira 100João Teodoro 100
- Page 162 and 163: Patricia Henriques Domingues 100Pat
- Page 164 and 165: ADMINISTRATIVE STAFFTime % at CNCAr
- Page 166 and 167: Sandra Isabel M. Cardoso (Auxiliar
- Page 168 and 169: Molecular Biotechnology and HealthE
- Page 170 and 171: Cell and Molecular ToxicologyLeonor
- Page 172 and 173: MicrobiologyMilton Costa, PhD, Coor
- Page 174 and 175: Paulo Gameiro Guerreiro 100Pedro Co
- Page 176 and 177: Marta Isabel Rodrigues Baptista 100
- Page 178: Url: http://www.cnbc.pt | Email: in